Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis.

Abstract

The coincident downregulation of NR4A1 and NR4A3 has been implicated in myeloid leukemogenesis, but it remains unknown how these two genes function in myeloid cells and how their combined downregulation promotes myeloid leukemogenesis. Since NR4A1 abrogation is thought to confer a survival and proliferation advantage to myeloid cells, we hypothesized that downregulation of NR4A3 may have a complementary effect on myeloid cell differentiation. First, we tested the association between differentiation status of leukemic cells and NR4A3 expression using two large clinical datasets from patients with different acute myeloid leukemia (AML) subtypes. The analysis revealed a close association between differentiation status and different subtypes of AML Then, we probed the effects of differentiation-inducing treatments on NR4A3 expression and NR4A3 knockdown on cell differentiation using two myeloid leukemia cell lines. Differentiation-inducing treatments caused upregulation of NR4A3, while NR4A3 knockdown prevented differentiation in both cell lines. The cell culture findings were validated using samples from chronic myeloid leukemia (CML) patients at chronic, accelerated and blastic phases, and in acute promyelocytic leukemia (APL) patients before and after all trans-retinoic acid (ATRA)-based differentiation therapy. Progressive NR4A3 downregulation was coincident with impairments in differentiation in patients during progression to blastic phase of CML, and NR4A3 expression was increased in APL patients treated with ATRA-based differentiating therapy. Together, our findings demonstrate a tight association between impaired differentiation status and NR4A3 downregulation in myeloid leukemias, providing a plausible mechanistic explanation of how myeloid leukemogenesis might occur upon concurrent downregulation of NR4A1 and NR4A3.

• Authors: Shih-Chiang Lin, Chi-Yuan Yao, Cheng-An Hsu, Chien-Ting Lin, Marcus J Calkins, Yuan-Yeh Kuo, Jih-Luh Tang, Hwei-Fang Tien, Shang-Ju Wu
• Journal: Annals of hematology (Ann Hematol) Vol. 101 Issue 10 Pg. 2209-2218 (Oct 2022) ISSN: 1432-0584 [Electronic] Germany
• PMID: 36040481 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• DNA-Binding Proteins
• NR4A3 protein, human
• Receptors, Steroid
• Receptors, Thyroid Hormone
• Tretinoin

Topics

• Cell Differentiation (genetics)
• DNA-Binding Proteins (genetics, metabolism)
• Down-Regulation
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Leukemia, Myeloid, Acute (drug therapy, genetics)
• Leukemia, Promyelocytic, Acute (drug therapy)
• Receptors, Steroid (genetics, metabolism, therapeutic use)
• Receptors, Thyroid Hormone (genetics, metabolism, therapeutic use)
• Tretinoin (pharmacology)